Esketamine for TRD: MOA, Application, and Adverse Events

Opinion
Video

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

Recent Videos
Geoffrey Grammer, MD, presenting slides
William Sauve, MD, presenting slides
Harman Deol, MD, presenting slides
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Related Content
Prescription Trends Between 2019 and 2022 Show the Rise of Telehealth

Prescription Trends Between 2019 and 2022 Show the Rise of Telehealth

Chelsie Derman
September 13th 2024
Article
The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

Kevin Kunzmann
January 11th 2024
Podcast
Patients on High Dose Amphetamine Face Over 5-Fold Psychosis, Mania Risk

Patients on High Dose Amphetamine Face Over 5-Fold Psychosis, Mania Risk

Chelsie Derman
September 12th 2024
Article
John J. Miller, MD: A New Era For Psychiatric Medications

John J. Miller, MD: A New Era For Psychiatric Medications

Kenny Walter
August 18th 2022
Podcast
Semaglutide Not Linked to Suicidal Risks in Those Without Major Psychiatric Disorders

Semaglutide Not Linked to Suicidal Risks in Those Without Major Psychiatric Disorders

Chelsie Derman
September 4th 2024
Article
Psychiatry Month in Review: August 2024

Psychiatry Month in Review: August 2024

Chelsie Derman
September 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.